144 related articles for article (PubMed ID: 15525861)
1. False-positive cancer screens and health-related quality of life.
McGovern PM; Gross CR; Krueger RA; Engelhard DA; Cordes JE; Church TR
Cancer Nurs; 2004; 27(5):347-52. PubMed ID: 15525861
[TBL] [Abstract][Full Text] [Related]
2. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
Taylor KL; Shelby R; Gelmann E; McGuire C
J Natl Cancer Inst; 2004 Jul; 96(14):1083-94. PubMed ID: 15265970
[TBL] [Abstract][Full Text] [Related]
3. The economic impact of false-positive cancer screens.
Lafata JE; Simpkins J; Lamerato L; Poisson L; Divine G; Johnson CC
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2126-32. PubMed ID: 15598770
[TBL] [Abstract][Full Text] [Related]
4. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
5. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
[TBL] [Abstract][Full Text] [Related]
6. Cumulative incidence of false-positive results in repeated, multimodal cancer screening.
Croswell JM; Kramer BS; Kreimer AR; Prorok PC; Xu JL; Baker SG; Fagerstrom R; Riley TL; Clapp JD; Berg CD; Gohagan JK; Andriole GL; Chia D; Church TR; Crawford ED; Fouad MN; Gelmann EP; Lamerato L; Reding DJ; Schoen RE
Ann Fam Med; 2009; 7(3):212-22. PubMed ID: 19433838
[TBL] [Abstract][Full Text] [Related]
7. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Weissfeld JL; Fagerstrom RM; O'Brien B;
Control Clin Trials; 2000 Dec; 21(6 Suppl):390S-399S. PubMed ID: 11189690
[TBL] [Abstract][Full Text] [Related]
8. Psychological impact of screening for familial ovarian cancer.
Wardle FJ; Collins W; Pernet AL; Whitehead MI; Bourne TH; Campbell S
J Natl Cancer Inst; 1993 Apr; 85(8):653-7. PubMed ID: 8468723
[TBL] [Abstract][Full Text] [Related]
9. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
10. Implications of false-positive results for future cancer screenings.
Taksler GB; Keating NL; Rothberg MB
Cancer; 2018 Jun; 124(11):2390-2398. PubMed ID: 29682740
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Quality Management (CQM) in the PLCO Trial.
Gohagan JK; O'Brien B; Hasson MA; Umbel KD; Bridgeman B; Kramer BS; Reding D; Gren L; Wright P; Riley T; Prorok PC
Rev Recent Clin Trials; 2015; 10(3):223-32. PubMed ID: 26238118
[TBL] [Abstract][Full Text] [Related]
12. Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center.
Gren LH; Lamerato LE; Wright P; Marcus PM
Rev Recent Clin Trials; 2015; 10(3):194-9. PubMed ID: 26238206
[TBL] [Abstract][Full Text] [Related]
13. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
14. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
15. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Miller AB; Yurgalevitch S; Weissfeld JL;
Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
17. Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
O'Brien B; Nichaman L; Browne JE; Levin DL; Prorok PC; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):310S-328S. PubMed ID: 11189685
[TBL] [Abstract][Full Text] [Related]
18. Distressed or relieved? Psychological side effects of breast cancer screening in The Netherlands.
Scaf-Klomp W; Sanderman R; van de Wiel HB; Otter R; van den Heuvel WJ
J Epidemiol Community Health; 1997 Dec; 51(6):705-10. PubMed ID: 9519137
[TBL] [Abstract][Full Text] [Related]
19. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Stallings FL; Ford ME; Simpson NK; Fouad M; Jernigan JC; Trauth JM; Miller DS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):379S-389S. PubMed ID: 11189689
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
